U.S., June 4 -- ClinicalTrials.gov registry received information related to the study (NCT07000955) titled 'Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity' on May 08.
Brief Summary: This study is a multicenter, randomized, partially double-blind (double-blind in both the IBI362 group and the placebo group, with the tirbopeptide group open), placebo and active drug controlled design study
Study Start Date: May 31
Study Type: INTERVENTIONAL
Condition:
Obesity
Intervention:
DRUG: Tirzepatide
Tirzepatide administered subcutaneously (SC) once a week.
DRUG: Placebo
Placebo administered subcutaneously (SC) once a week.
DRUG: IBI362
IBI362 administered subcutaneously (SC) o...